Stryker (SYK) is lower today as the market de-risks into its next earnings report, with traders focused on whether management flags any residual impact from the March 2026 cyberattack. The stock’s pullback looks driven more by event risk and uncertainty around near-term execution than by a single new headline.

Stryker disclosed a cyber incident in March that disrupted portions of its global operations and internal systems, which elevated concern about order processing, manufacturing, and shipping continuity. More recently, the company said operations were fully restored and it did not expect a material impact to full-year 2026 guidance, but investors are still looking for hard numbers on Q1 disruption, recovery costs, and any knock-on demand effects.

Key items that could determine the next leg for SYK include: (a) organic revenue growth versus expectations, (b) commentary on backlog/order normalization and any missed shipments pushed into Q2, (c) gross margin performance amid temporary workarounds and expedited logistics, and (d) explicit disclosure on cyber-related costs (IT remediation, outside advisors, hardware replacement, and incremental security spend). If Stryker reiterates its full-year outlook while showing limited Q1 operational slippage, pressure could ease; any hint of lingering friction could extend the stock’s recent weakness.

The move also fits with a broader pattern in medtech where high-quality compounders can still trade down into earnings when uncertainty rises, especially after an operational shock like a cyber incident. With SYK near its 52-week lows, the market is signaling it wants clarity on execution and risk controls before re-rating the stock higher.